As part of an important move towards greater transparency and building improved trust and confidence between the medical community, pharmaceutical industry and patients across the UK, The Association of the British Pharmaceutical Industry (ABPI) requires companies to publicly declare, payments made to Healthcare Professionals (HCPs), Other Relevant Decision Makers (ORDMs), Healthcare Organisations (HCOs) and Patient Associations made annually, at an individual level on a centrally managed Central Platform. Flynn Pharma intends to support this process in full and commits to submitting all data in accordance with the instructions issued by the ABPI.
2017 Grants and Donations to Healthcare Professionals and Other Relevant Decision Makers
In 2017, Flynn Pharma Ltd. made transfers of value totalling £102,736.47 to 809 UK-based HCPs and ORDMs for providing advice and consultancy, including chairing, and/or speaking at educational meetings, attendance at educational meetings, assistance with training and participation in advisory boards and market research-based activities. Full details of these transfers of value, made at an individual level (where consent to disclose has been granted), will be accessible via the Central Platform from July 2018. The average transfer of value made to UK-based Healthcare Professionals was £126.99 (range £2,500 - £47.66).
2017 Grants and Donations to Healthcare Organisations and Patient Associations
Flynn Pharma Ltd. provides grants and donations to European and UK Healthcare Organisations and Patient Associations to support their work designed to benefit patient care, the purchasing of medical equipment, research where Flynn Pharma Ltd. is not directly involved in the activity, to support their employees/ members to undertake medical education run by independent third parties, to enhance service development and support their day-to-day activities. In 2017, Flynn Pharma Ltd. made transfers of value totalling £196,350.57 to 518 UK Healthcare Organisations and Patient Associations. Full details of these transfers of value, made at an organisational level (and where consent has been granted), will be accessible via the Central Platform from July 2018.
Considering these transfers of value made by Flynn during 2017 in more detail, the average transfer of value received by HCOs in the UK was £379.06 per HCO. Breaking this down further, 5% of HCOs (the 26 organisations who received the largest transfers of value) received £147,914.46 at an average of £5,689.02 (range £44,760.00 – £657.59) per HCO which represents 75% of the overall transfers of value made to HCOs; the remaining 95% of HCOs (492 organisations) received £48,436.11 which represents 25% of the overall transfers of value made to HCOs at an average of £98.45 per HCO. Ten percent of HCOs (the 52 organisations who received the largest transfers of value) received £159,784.19 at an average of £3,072.77 (range £44,760.00 – £373.25) per HCO which represents 81% of the overall transfers of value made to HCOs; the remaining 90% of HCOs(466 organisations) received £36,566.38 (range £371.35 - £6.70) which represents 19% of the overall transfers of value made to HCOs at an average of £78.47 per HCO.
2017 Clinical Research and Charitable Donations
Flynn Pharma Ltd. provides grants and donations to UK-based charities, patient associations, clubs, schools and community organisation to support their work and charitable aims.
Flynn Pharma Ltd. provides grants to support Clinical Research initiatives in the UK where Flynn Pharma Ltd. is not directly involved in carrying out the research.
Flynn Pharma Ltd. is pleased to make the following declarations in relation to Charitable Donations and to Clinical Research (at an aggregate level);
- Charitable Donations of £4,195 (for further information click here)
- Support for Clinical Research carried out within the UK, £23,723.12
Date of preparation January, 2018